Objectives/Hypothesis: NR4A1 was recently identified as an endogenous inhibitor of transforming growth factor (TGF)-b-induced fibrosis, and the role of this nuclear receptor has not been elucidated in tissue health or the response to injury in the vocal folds. Given the clinical implications of vocal fold fibrosis, we investigated NR4A1 expression during vocal fold wound healing in vivo and the regulatory roles of NR4A1 on vocal fold fibroblasts (VFFs) in vitro with the ultimate goal of developing targeted therapies for this challenging patient population.
INTRODUCTION
The etiology of fibrosis of the vocal folds (VFs) is diverse. Following injury, healthy pliable tissue is replaced by fibrous scar resulting in aberrant vibratory function and intractable dysphonia. 1 Transforming growth factor (TGF)-b has a wide range of biological functions and plays a critical, regulatory role in wound repair. Under normal physiological conditions, TGF-b transiently increases following injury to stimulate quiescent fibroblasts into activated myofibroblasts that express a-smooth muscle actin (a-SMA), 2 which have contractile features and synthesize extracellular matrix (ECM) resulting in contraction and maturation of granulation tissue in early wound healing. 3 Myofibroblast dedifferentiation and apoptosis typically occur as healing progresses to the more chronic stages. However, in fibrosis, exuberant TGF-b signaling sustains myofibroblast activation to continually synthesize ECM, resulting in aberrant architecture and function. [4] [5] [6] Strategies to alter TGF-b signaling likely hold therapeutic promise for VF fibrosis, a particularly challenging clinical entity. 7, 8 The development of physiologically relevant therapeutics for fibrosis in general, and more specifically, VF scar requires increased insight into the biochemical mechanisms underlying these aberrant processes. Our group previously reported TGF-b signaling was Smad3-dependant in VF fibroblasts, 9 and RNA-based therapy to alter Smad3 expression may evolve into the clinical milieu to limit the TGF-b1-mediated profibrotic phenotype. 10, 11 However, an alternative approach has evolved. Orphan nuclear receptor 4A1 (NR4A1, also known as NUR77, TR3, NGFI-B, or NAK-I) belongs to the nuclear receptor subfamily 4 group A (NR4A), which are implicated in multiple cell processes including proliferation, differentiation, apoptosis, metabolism, and development. 12, 13 NR4A receptors are rapidly induced across tissue systems, and NR4A1 has been implicated in metabolic, cardiovascular, and neurogenic diseases as well as arthritis, cancer, and other inflammatory and immunologic conditions.
14 Recently, NR4A1 deficiency increased TGF-b signaling and exacerbated fibrosis in murine models of skin and lung fibrosis. Conversely, NR4A1 inhibited TGF-b signaling in mice overexpressing TGF-b receptor type I. 15 Specifically, an NR4A1 agonist decreased TGF-b target gene expression, including collagen, and limited experimentally induced fibrosis. We hypothesize that NR4A1 is an ideal target to regulate intracellular TGF-b signaling, and ultimately, treat and/or avoid VF scar.
In the current study, we investigated the putative regulatory role of NR4A1 in VF injury and repair. Specifically, we sought to characterize the temporal dynamics of NR4A1 expression following VF injury and quantify the effects of altered NR4A1 signaling on downstream, TGF-b1-mediated transcriptional and regulatory profibrotic events in VF fibroblasts.
MATERIALS AND METHODS
In Vivo VF injury. The current protocol was approved by the Institutional Animal Care and Use Committee at the New York University School of Medicine. Thirty-six, 14-week-old, female Sprague-Dawley rats underwent unilateral VF injury as previously described. 16 Briefly, following paralytic anesthesia via intraperitoneal injection of ketamine hydrochloride (90 mg/kg) and xylazine hydrochloride (8 mg/kg), animals were placed on a custom operating platform in a near-vertical position, and the larynx was visualized via a 2.7-mm, 0 8or 30 8 telescope (Karl Storz, Flanders, NJ) coupled to a camera and video monitor. The right VF was injured by separating the lamina propria from thyroarytenoid muscle by inserting a 25-gauge needle at the lateral edge of the right VF. The lamina propria was then removed with microforceps. Six animals were randomized into seven experimental groups based on time of sacrifice: 0 (e.g., uninjured control), 1, 3, 7, 14, 30, and 90 days following injury. Following sacrifice, the larynx was harvested and the bilateral VFs were dissected under magnification. VFs from four animals were subjected to gene analysis and two were prepared for immunohistochemistry.
Immunohistochemistry. Upon harvest, the larynges were fixed in 4% paraformaldehyde for 3 hours and then in 30% sucrose for 24 hours at 4 8C. After embedding in Optimum Cutting Temperature formulation (Tissue-Tek, Torrance, CA), the samples were frozen, and 10-mm serial coronal sections were prepared. Sections including the mid-portion of the VFs were permeabilized and blocked with a solution containing 0.1% Triton-X and 5% normal goat serum, then incubated in primary rabbit monoclonal antibody against NR4A1 (1:100; SigmaAldrich, St. Louis, MO) overnight at room temperature. The slides were washed and incubated for 1 hour at room temperature, and Alexa-Flour 555 anti-rabbit IgG (1:300; Abcam, Cambridge, MA) was employed as the secondary antibody. Nuclei were counterstained by 4 0 , 6-Diamidino-2-phenylindole dihydrochloride (DAPI) (Thermo Scientific, Waltham, MA). For negative controls, the primary antibodies were omitted. Stained sections were visualized, and images were captured using a Nikon Eclipse Ni-U fluorescence microscope (Nikon Inc., Tokyo, Japan). All images were captured at 10 3 or 60 3 magnification.
Quantitative real-time polymerase chain reaction. Total RNA was extracted from the tissue via the RNeasy Mini Kit (Qiagen, Valencia, CA). RNA was reverse transcribed with a High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA). Quantitative reverse-transcription polymerase chain reaction (qRT-PCR) employed the TaqMan Gene Expression kit (Life Technologies, Waltham, MA) and StepOne Plus (Applied Biosystems). Taqman primer probes for Nr4a1 (Rn01533237_m1) and Gapdh (Rn01775763_m1) were employed. The DDCt method was employed with Gapdh as the housekeeping gene.
In Vitro
Cell culture. An immortalized human VF fibroblast cell line created in our laboratory was employed for all in vitro experimentation. This cell line, referred to as HVOX, has been shown to be stable through multiple population doublings 9 ; cells in passages 20 to 30 were used. Cells were cultured on 6-well plates in Dulbecco's Modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% antibiotic/ antimycotic at 37 8C under standard cell culture conditions. Following 12-hour serum starvation, HVOX were treated with serum-free DMEM 1 TGF-b1 (10 ng/mL) and then harvested at appropriate time points to investigate the temporal dynamics of NR4A1 gene expression in response to TGF-b1 stimulation. Recombinant human TGF-b1 (Life Technologies, Grand Island, NY) was employed for cell stimulation.
Transfection. siRNA was then employed to knockdown NR4A1 expression. HVOX were transfected with 1pM of NR4A1 siRNA (Ambion, Grand Island, NY) in 2.5-ml of Lipofectamine 2000 (Invitrogen, Carlsbad, CA) for 6 hours. The transfection media was then replaced with fresh DMEM supplemented with 10% FBS; the cells were harvested every 24 hours for 96 hours to examine the duration of knockdown efficiency. Nonsense siRNA (Ambion) served as a control. To confirm effective NR4A1 knockdown, RNA extraction and quantification was performed as described previously, and qRT-PCR was performed employing NR4A1 (Hs00374226_m1) and GAPDH (Hs02758991_g1) primer probes.
Gene analysis. After transfection, cells were cultured in complete media for 48 hours. After 12 hours starvation, cells were treated with serum-free DMEM 1 TGF-b1 (10 ng/mL) and harvested at 4 or 24 hours. As described previously, qRT-PCR was then performed employing the following primer probes:
, SERPINE1 (Hs00167155_m1, TGF-b1 (Hs00998133_m1), and GAPDH.
Cell staining. Transfected HVOX were grown on chamber slides for 2 days under each experimental condition. Cells were fixed in 4% paraformaldehyde and then permeabilized and blocked via a phosphate-buffered saline solution containing 0.1% Triton-X and 5% normal goat serum. The slides were incubated at 4 8C overnight with primary mouse monoclonal antibodies against a-SMA (1:100; Sigma-Aldrich) and then the corresponding Alexa-Fluor 555 goat anti-mouse immunoglobulin G (1:500; Invitrogen) secondary antibody. Nuclei were counterstained with DAPI. Digital images were captured, and both the total cell count and a-SMA-positive cells were counted in 10 randomly chosen, 3.0-mm 2 fields for each condition under 10 3 magnification.
Collagen gel contraction. The gel contraction assay was performed according to our previous report. 11 Briefly, collagen gels were created using PureCol (Advanced BioMatrix, San Diego, CA) as previously reported 17 using 0.5-inch Teflon rings. HVOX were gently pipetted onto gels at a concentration of 3.0 3 10 4 cells in 200-lL complete media and incubated for 2 hours. The gels were then submerged in each media condition supplemented with 1% FBS. Gels were imaged at 0 and 12 hours using a digital 8-megapixel camera (Apple, Inc., Cupertino, CA). Contraction was quantified by measuring the gel area in pixels using ImageJ (National Institutes of Health, Bethesda, MD). Percent contraction was then calculated via initial areafinal area/initial area (%).
Statistical Analyses
For both in vivo and in vitro NR4A1 mRNA expression time course experiments, a one-way factorial analysis of variance was employed to determine a significant main effect, followed by Bonferroni/Dunn post hoc comparisons to investigate differences in gene expression at each time point relative to control. For the remaining in vitro assays, a Student t test was Fig. 1. (A) Nr4a1 mRNA expression changes following rat vocal fold injury. Nr4a1 gene expression increased from 1 day to its peak at 7 days, significant differences were observed at 3 days and 7 days compared to control. Data presented as mean 6 standard deviation of assays run in triplicate (N 5 4; *P <.05). (B) Representative images of immunofluorescence staining for NR4A1. NR4A1-expressing cells emerged 1 day following injury. Staining was observed in the peripheral edge of the injured site at 3 days and spread along the surface of the lamina propria. NR4A1 expression gradually decreased until 90 days, and returned to near baseline (day 0 control). Images were captured at 4 3 magnification or 60 3 magnification (the white boxed areas are shown magnified). Blue, DAPI and red, NR4A1. Scale bar length designated in figure. DAPI 
RESULTS

In Vivo
Nr4a1 gene expression increased following VF injury. Nr4a1 mRNA expression increased 1 day following injury (Fig. 1A) . This increase, however, did not achieve significance. Nr4a1 further increased 3 (P 5.021) and 7 (P <.001) days following injury with a return to baseline by 90 days, the endpoint of the current study. Immunohistochemical localization of NR4A1 expressing cells was performed. NR4A1 expressing cells emerged 1 day following injury (Fig. 1B) . Positive cells were observed at the wound periphery 3 days following injury. By day 7, NR4A1 expressing cells were observed along the surface of lamina propria concurrent with epithelialization. Beyond 7 days, limited NR4A1 expression was observed around the peripheral edge of the injured site; NR4A1 expression decreased until 90 days.
In Vitro TGF-b1 stimulated NR4A1 mRNA expression. The fundamental biological features of human VF fibroblasts were investigated before proceeding to further experimentation. As shown in Figure 2A , NR4A1 mRNA was upregulated under TGF-b1 stimulation; significantly increased NR4A1 expression was observed between 1 and 8 hours, with peak expression at 3 hours (P <.001). As shown in Figure 2B , NR4A1 gene expression was decreased by greater than 80% with siRNA; transfection efficiency was sustained for 96 hours after the transfection media was replaced with complete media (P <.001 for all time points).
Decreased NR4A1 mRNA expression altered TGF-b1-mediated transcriptional events. Knockdown of NR4A1 mRNA expression was confirmed in TGF-bstimulated cells at 4 hours (P <.001; Fig. 3A ). At this time point, SMAD7 was significantly upregulated in the siRNA NR4A1 (Si-NR4A1) condition (P 5.002), whereas neither SMAD2 nor SMAD3 expression were affected by Si-NR4A1 under TGF-b stimulation (Fig. 3B-D) . At 24 hours, COL1A1 and SERPINE1 were significantly upregulated in Si-NR4A1 transfected cells compared to control under TGF-b stimulation (P <.001, P 5.004, respectively; Figure 3E ,F). TGF-b1 mRNA expression also increased in response to NR4A1 knockdown (P <.001; Fig. 3G ).
NR4A1 knockdown enhanced myofibroblast differentiation. As shown in Figure 4A , TGF-b1 stimulation appeared to alter both cell size and the appearance of stress fibers; increased a-SMA expression was observed with NR4A1 knockdown. The ratio of a-SMApositive cells significantly increased in the Si-NR4A1 condition (P 5.013; Fig. 4B ).
TGF-b-mediated collagen gel contraction was accelerated with knockdown of NR4A1. As shown in Figure 5A , stimulatory effects of TGF-b1 on gel contraction were observed, and this response accelerated with Si-NR4A1 knockdown (P 5.002; Fig. 5B ).
DISCUSSION
The primary biological goal of the inherent tissue response to injury is regeneration of tissue. However, in the VFs and many other tissues, scar formation is relatively common with significant clinical morbidity. Globally, excessive and/or sustained TGF-b presence in the wound milieu has been implicated in a variety of fibrotic disease processes. 3 In the VFs, TGF-b transcription is observed as early as 8 hours following injury 18 and cell activation is maintained until chronic scar maturation. 19 Direct therapeutic regulation of either TGF-b signaling or downstream antagonists of TGF-b are likely to ultimately hold significant clinical promise. In that regard, Palumbo-Zerr et al. 15 recently suggested that NR4A1 was an endogenous inhibitor of TGF-b. The dynamics of NR4A1 in VF injury have not yet been described. Identifying key biochemical targets for intervention are particularly relevant given that the VFs are an ideal model for the direct application of therapeutics via inoffice, awake procedures.
Nr4a1 mRNA expression increased from day 1 to day 30 following VF injury, with significant upregulation between day 3 and day 7. This temporal pattern concurs with previous reports of TGF-b1 upregulation following VF injury. 20 Taken together with our in vitro data that NR4A1 upregulation was induced by short-term TGF-b1 stimulation, NR4A1 expression appears to be highly related to TGF-b1 metabolism following injury. With regard to localization, NR4A1 was observed in the epithelium at the peripheral edge of the wound site acutely, and thereafter, along the surface of the injury site 1 week following injury. Interestingly, Tateya et al. previously reported re-epithelialization of injured rat VFs around 1 week after injury. 16 Although not investigated, it is likely that re-epithelialization is highly related to migration and synthesis of neomatrix by cells at the peripheral edge of the epithelial defect, and further investigation is warranted to provide mechanistic insight into these processes and to provide optimal timing and/ or location of treatments targeting NR4A1 in vivo.
Knockdown of NR4A1 induced upregulation of ECM genes, especially collagen encoding genes, and increased myofibroblast differentiation and contraction suggesting enhancement of the profibrotic features of TGF-bstimulated VF fibroblasts. As secondary messengers of TGF-b stimuli, Smad2 and Smad3 expression were not affected by NR4A1 regulation. TGF-b1 was previously reported to stimulate Smad3-Smad4-SP1 complex binding to SP1 binding sites and promote downstream NR4A1 expression. 15 Our data concur with these findings in that the Smad2/Smad3 complex is located upstream of NR4A1 and independent from NR4A1 manipulation. Smad7 upregulation with NR4A1 knockdown also concurs with previous data; upregulation of Smad7 is thought to be antifibrotic, as Smad7 is a competitive inhibitor of Smad3 heterodimerization. NR4A1 knockdown lead to enhanced myofibroblast differentiation and collagen contraction in response to TGF-b. Cumulatively, these data suggest the potential antifibrotic effects of NR4A1. However, the current study is not without limitation. In persistent TGF-b activation characteristic of fibrotic disease, phosphorylation of NR4A1 appears critical. 15 As mentioned previously, NR4A1 transcription is regulated by Smad-SP1 complex. Furthermore, NR4A1 itself recruits complexes that include SP1 and silence downstream TGF-b target genes such as type I collagen. In contrast, phosphorylated NR4A1 cannot bind SP1, thereby diminishing its role as a suppressor of TGF-b signaling. Further investigation is needed to clarify the relationship between phosphorylated NR4A1 and VF fibroplasia.
Regardless, NR4A1 knockdown promoted and enhanced TGF-b-mediated profibrotic features in VF fibroblasts. As such, activation of NR4A1 could be a promising candidate to suppress TGF-b signaling and exert a therapeutic effect on TGF-b-mediated fibrotic disease processes. In that regard, Cytosporone B (Csn-B) has a strong affinity for NR4A1 and has been shown to stimulate NR4A1 activation. 21 Furthermore, PlumboZerr et al. reported that Csn-B ameliorated fibrosis in multiple experimentally induced models of fibrosis including chronic/mature fibrosis. 15 The VFs are an ideal model for novel, targeted therapeutics including Csn-B given their anatomical location for localized injection to avoid systemic side effects.
CONCLUSION
Globally, NR4A1 appears to be a potent regulator of TGF-b signaling across fibrotic conditions including the VFs. NR4A1 expression increased following VF injury. In addition, knockdown of NR4A1 enhanced the profibrotic effects of TGF-b stimulation in VF fibroblasts including myofibroblast differentiation and contraction in addition to regulation of profibrotic transcriptional events. These data provide a foundation for establishing novel strategies for targeting NR4A1 for VF fibrosis. 
